



MSTS Newsletter

Volume 322, Winter 2024

Inside this Issue

President’s Report1	2024 Dues Reminder5	Hatcher Fellowship Applications Open . . 9
2024 Annual Meeting-Save the Date . . .3	2023 Annual Meeting Abstract	Welcome New MSTS Members11
MSTS Executive Committee3	Award Recipients7	Thank You MSTS Donors!11
Join us at MSTS Specialty Day 20245	Metastatic Bone Disease Task Force7	Thank You MSTS Sponsors!13
	Guidelines and EBM Committee9	

President’s Report – Benjamin J. Miller, MD, MS



Benjamin J. Miller, MD, MS

Greetings and warm wishes (especially to those in the more frozen parts of the world) to all members of the MSTS! It is my privilege to provide an update

on the immediate past and future goals of the Executive Committee. To start, I would like to thank and recognize Kerri Mink and Deborah Meyer for their administrative support of the Society and superior execution of the annual meeting. I am so fortunate to be surrounded by an engaged group of dedicated surgeons, teachers, and thinkers on the Executive Committee – ideas and enthusiasm abound and all for the good of our members, trainees, and patients.

2023 Annual Meeting: The picturesque setting in the Canadian Rockies of Banff, Alberta could only be overshadowed by the depth of scientific presentations and two engaging speakers (Adam Shoalts and Gordon Guyatt). Dr. Guyatt in particular gave an overview of the origin and maturation of the concept of Evidence-Based Medicine and gave us all a reason to leave the meeting feeling motivated and

educated. The Annual Meeting continues to be *the* event of the MSTS calendar and provides an opportunity for presenting research, sharing ideas, and connecting with old and new friends. Congratulations to Michelle Ghert, Jay Wunder, and Peter Ferguson for a truly memorable experience.

2024 Specialty Day: With the 2023 Annual Meeting over, the next event for the Society is MSTS Specialty Day during the 2024 AAOS Annual Meeting in San Francisco. Please note that Specialty Day is on Friday, February 16 (no longer on Saturday) and features an engaging program arranged by Melissa Zimel, Luke Nystrom, and Panos Papagelopoulos. Specialty Day differs from the Annual Meeting in the opportunity to explore areas of our practices or professional lives apart from scientific abstracts. Topics are wide-ranging and include updates and tips on collaborative research projects, open and closed pelvic fixation techniques, newer interventions for patients with metastatic bone disease, practice management, legal issues, industry consulting, advocacy, international training, and mentorship. Michael Rabow will give the keynote address “Caring for the Caregiver.” In all, this is a program that will highlight many issues important to ourselves, our profession, and our patients. I hope to see you all there!

Committees and Task Forces: While several of our committees continue with experienced and effective leadership (Tae Kim – Communications and Technology, Adam Levin – Practice Management, Nick Tedesco – Guidelines and Evidence-Based Medicine), several important committees have new chairs. We welcome Bang Hoang – Research, Ginger Holt – Education, Santiago Lozano-Calderon – Fellowship, and Odion Binitie – Membership. It has been great to see all the fresh ideas and perspectives that accompany new leadership and I look forward to helping ensure each committee has success in realizing their respective visions. Phil Wodajo continues to shepherd the Metastatic Bone Disease Task Force through its second phase of its mandate, and Raj Rajani is just ramping up with the newly-established Advocacy Task Force. Our Society is fortunate to have all of these engaged committee chairs and committee members and I encourage anyone who wants to take an active role in the MSTS to apply for any open committee seats this summer, or any other time there is a call to serve on a committee, task force, or work group.

Musculoskeletal Tumor Registry: The MSTR continues to mature and evolve. The main goals of this year are to increase participation and enrollment of interested

Continued on page 3

MSTS Headquarters

1515 E. Woodfield Road, Suite 345

Schaumburg, IL 60173

info@msts.org

847/698-1625



Introducing...

The Juvenile Tumor System from Onkos Surgical®

An extendible implant that allows for noninvasive bone lengthening in children following lower limb-sparing surgery



The leading 510(k) cleared solution in the U.S. for noninvasive lengthening of a pediatric limb reconstruction device



Designed to grow with the child and stay with them throughout their adult life



Helps reduce the risk of surgical complications associated with limb reconstruction in pediatric cancer patients



Over 1,100 JTS devices have been implanted worldwide

Visit us in the MSTs Exhibit Hall.

2023 MSTs Diamond Supporter

Contact us to learn more:

973.264.5400 | onkossurgical.com

Disclaimer: A surgeon should rely exclusively on his or her own professional medical/clinical judgment when deciding which particular product to use when treating a patient. ONKOS SURGICAL does not prescribe medical advice and advocates that surgeons be trained in the use of any particular product before using it in surgery. A surgeon must always refer to the product label and/or instructions for use before using any ONKOS SURGICAL product.

ONKOS SURGICAL, ELEOS, BioGrip, My3D, and GenVie are all registered marks and trademarks of Onkos Surgical. © 2023 ONKOS SURGICAL. All rights reserved. CORP 08.8.23 v0

Precision Orthopaedics

- ELEOS™ Limb Salvage Solutions
- My3D® Personalized Solutions
- GenVie® Regenerative Biologics



institutions and continue to audit and improve data accuracy and completeness. The focus will be on the Sarcoma Module, for which smartforms are currently available for download on the "Turbocharger" platform for those who use Epic as their Electronic Health Record. Our goal is to expand the smartform accessibility to include more universal options, such as REDCap, and to introduce a Metastatic Bone Disease Module. Thanks to Nate Mesko and Adam Levin for their leadership in issues of data integrity and publications, respectively. Eric Henderson continues to lead a multidisciplinary and multi-institutional team preparing for a PCORI grant submission in late 2024. We have formed a Patient and Caregiver Committee to help us ensure the registry and grant application reflect the true challenges and successes of sarcoma care as experienced by those most closely and personally affected.

2024 Annual Meeting: Although Banff was only 3 months ago, it's already time to get excited about next year's Annual Meeting in Chicago September 11-13. Luke Nystrom has just begun to lead the planning committee but the meeting is already starting to take shape. In addition to the usual expectation of a stellar scientific lineup, we will be offering an Allied Health Program and Pathways on Wednesday prior to the start of the meet-

ing. Pathways is a new idea that will allow for MSTs members at all levels of training and experience to discuss various areas of professional development or interest, including education, clinical trials, basic science, innovation, and leadership. Stay tuned on future announcements regarding a fellows' course, presidential speakers, and a hands-on minimally invasive periacetabular skeletal intervention workshop.

Overall, we are off and running in 2024! If anyone has any comments, ideas, or otherwise, please do not hesitate to reach out to me or the other members of the Presidential Line (Michelle Ghert, Raj Rajani, Francis Lee, Matt DiCaprio).

See you all in San Fran!

Save the Date

Please save the date for the MSTs 2024 Annual Meeting! This year's meeting will take place September 11-13 at the Sheraton Grand Riverwalk in Chicago, IL.

Watch the [MSTs website](#) for the preliminary agenda, information on housing, room rates, and meeting registration.

Prepare your abstracts now! The call for abstracts will open on March 4, 2024. April 1, 2024 is the deadline to submit abstracts for the 2024 MSTs Annual Meeting.

We look forward to seeing you in Chicago!



MSTs Executive Committee

President

Benjamin Miller, MD
benjamin-j-miller@uiowa.edu

President-Elect

Rajiv Rajani, MD
rrajani@ttuhsc.edu

Secretary

Francis Y. Lee, MD, PhD
francis.lee@yale.edu

Treasurer

Matthew R. DiCaprio MD
mdicaprio15@gmail.com

Immediate Past President

Michelle Ghert, MD, FRCSC
ghertm@mcmaster.ca

Past President

Michael P. Mott, MD
mmott2@hfhs.org

Education Committee

Ginger Holt, MD
ginger.e.holt@vumc.org

Research Committee

Bang Hoang, MD
bahuang@montefiore.org

Membership Committee

Odion Binitie, MD
odion.binitie@moffitt.org

Members-at-Large

Alan Blank, MD
alan_blank@rush.edu
David D. Greenberg, MD
david.greenberg@health.sluc.edu



Is repetitive surgery the best option for patients with Pigmented Villonodular Synovitis (PVNS) or Tenosynovial Giant Cell Tumor (TGCT)?

If you have a patient symptomatically affected by PVNS (or TGCT) who is not a candidate for surgery, they may qualify for the MANEUVER study. Study related patient care and travel are covered in N. America for qualifying patients.

Please get in touch with us, via clinical@abbisko.cn (for the medical physician only)

For more information, scan the QR code.



About the MANEUVER Study (ABSK021-301)

The MANEUVER Study (ABSK021-301), is a ph. III clinical study of ABSK021 (Pimicotinib) in Patients with Tenosynovial Giant Cell Tumor to determine whether the study drug is safe and to measure the antitumor activity of the study drug.

FDA granted a **Breakthrough Therapy Designation** based on the preliminary data from Phase I clinical trial, and the Phase III global trial launched successfully. We are partnering with referring MDs to assist in meeting enrollment for this important study.



Abbisko

Join Us at 2024 MSTs Specialty Day

We look forward to seeing you in the vibrant city of San Francisco! We are so excited to host this event and appreciate you stepping away from the demands of life to join us for the 2024 MSTs Specialty Day!

Our program is the result of a tremendous collaboration with the MSTs membership and beyond. We hope to inspire new ideas, debate, and connections! We wouldn't be here without you, our friends and colleagues, so THANK YOU to all of the speakers and others who contributed their time and support, especially Kerri Mink and Deborah Meyer!

Looking for ways to become more engaged in research? Look no further than our morning session led by Dr. Wakenda Tyler, Deputy Editor for the Oncology section of JAAOS. After hearing how you can contribute to the journal, Dr. Lorenz will report on his Sarcoma Strong-sponsored research. Dr. Ghert will update us on the progress of PARITY, and Dr. Miller will share strategies for overcoming obstacles with the MSTs-AAOS Registry. Closing out the session, Dr. Balach will provide a comprehensive review of all current multi-institutional research opportunities for MSTs members who wish to join forces.

Dr. Francis Lee will kick-off our second session of the morning, detailing successes, failures, and everything in between with percutaneous pelvis fixation. Dr. Kim and Dr. Yang will enlighten us with their experiences with percutaneous fixation with and without tumor ablation. For an update on the victories and defeats of open pelvis reconstruction with custom implants, we will hear from Dr. Wustrack and Dr. Papagelopoulos. Lastly, Dr. Lewis will impart her wisdom comparing custom pelvic reconstruction to no reconstruction after pelvic tumor resection.

Dr. Wodajo, head of the MSTs Metastatic Bone Disease Taskforce, will lead our multidisciplinary session on "Caring for Patients with Metastatic Bone Disease." We have assembled an extraordinary group of experts discussing radiation ther-

apy, optimizing bone health, interventional palliative pain procedures, and medical pain management. Our Keynote Speaker, Dr. Michael Rabow, Professor of Clinical Medicine, and Director of the Palliative Care Program at UCSF, will impart his wisdom during his address on "Caring for the Caregiver."

Spearheading our first afternoon session, Dr. Bukata will enliven the discussions on practice management, including updates on billing and coding to optimize reimbursement with Dr. Levin, and negotiating salaries and value with Health Systems with Dr. Morris. Dr. Mesko will review the state of legal challenges in oncology and Dr. Rajani will detail the experience of being an expert witness. Lastly, Dr. Randall will share insider tips on industry consulting.

We will close the day with Dr. Kemp spotlighting the new MSTs Advocacy Task Force and how MSTs Gives Back! Dr. Miller will share his experience with establishing an international Orthopedic Oncology Fellowship and Dr. Conrad will highlight decades of partnership with patient advocacy groups. Dr. DiCaprio will teach us how to grow philanthropic efforts, and Dr. Bradford will embolden us to sponsor the next generation of orthopedic surgeons by partnering with Nth Dimensions. Lastly,

Dr. Cipriano will share how to support the orthopedic pipeline by collaborating with the Ruth Jackson Orthopedic Society and the Perry Program.

We hope you will enjoy all that we've packed into this day and that you will leave inspired and fulfilled! See you in San Francisco!

[Click here to register today!](#)

Sincerely,

Melissa Zimel, MD, Lukas Nystrom, MD, and Panos Papagelopoulos, MD, FACS
MSTs Specialty Day Planning Committee



2024 Dues Reminder

Your 2024 MSTs membership is now due. If you have not yet paid your 2024 dues, we ask that you make your payment now.

Emails regarding dues are sent from msts@memberclicks-mail.net. The email includes a link to your dues invoice. Simply click on the link in your email to pay your dues by credit card – no login or password is required.

If you have questions regarding your dues, or if you would like to make the dues payment by phone, please contact us at 847-698-1625.



Ogsiveo[™]
(nirogacestat)
50 mg tablets

NOW APPROVED

For Prescribing Information, how to order,
patient support, and more,
visit [OGSIVEO.com/hcp](https://ogsiveo.com/hcp)



MSTS Congratulates the 2023 Annual Meeting Abstract Award Recipients

MSTS received 244 outstanding abstract submissions for consideration for presentation at the 2024 Annual Meeting. The Annual Meeting Planning Committee carefully reviewed each abstract, paper, and poster presentation and MSTS is pleased to recognize the following recipients who were selected to receive 2023 Abstract Awards. Congratulations to each of the recipients!

Best Paper Presentations

- **1st Place** - The Development of a 14-Item Patient-Reported Lower Extremity Functional Tool for Orthopaedic Oncology Surgical Patients Using the TESS and LEFS, presented by *Shalin S. Patel, MD*
- **2nd Place** - Disruption of Cks1 and Skp2 Reveals a Novel Therapeutic Target in Osteosarcoma, presented by *Ranxin Zhang, MD*
- **3rd Place** - Surgery Sooner? A Condensed Treatment Course Yields Excellent Outcomes in Localized Soft Tissue Sarcomas, presented by *Meena Bedi, MD*

Best Poster Presentations

- **1st Place** - "The Efficacy of Exparel Versus a Multidrug Cocktail in Soft Tissue Tumors" Preliminary Findings, presented by *James C. Wittig, MD*
- **2nd Place** - The Impact of Osseous Erosions on Intra-Articular Tenosynovial Giant Cell Tumors and Local Recurrence, presented by *Jarod Olson*
- **3rd Place** - Discovery of a Novel Tubulin Code in Bone Metastasis of Breast Cancer, presented by *Alan T. Blank, MD, MS*

Young Investigator

- **1st Place** - Mouse Models of Kidney Cancer Bone Metastasis Demonstrate Cachexia, presented by *Christopher D. Collier, MD*
- **2nd Place** - Uncovering Immunomodulatory Mechanisms Associated with Chronic Implant Associated Infections, presented by *Christopher Hamad, MD*

- **3rd Place** - Reducing the Risk of Radiation Associated Fractures Through Exosome Based Periosteal Regeneration, presented by *Joshua Labott, MD*

Best Collaborative Study

- Efficacy and Safety of Vimseltinib in Tenosynovial Giant Cell Tumor (TGCT): Phase 2 Expansion, presented by *Nicholas M. Bernthal, MD*

Metastatic Bone Disease Task Force – Felasfa Wodajo, MD, Chair

In March 2022, the Executive Committee of (EC) the MSTS voted to convene a Task Force that will develop a strategy that will drive the Society to better address the needs of patients with metastatic bone disease, as well its members, nearly all of whom devote a significant portion of their practice to treating these patients.

The Task Force that was formed consisted of orthopedic oncologists, spine surgeons, radiation oncologists, medical oncologists, and interventional radiologists. The Task Force worked in five committees to produce recommendations on the following topics:

1. Annual Meeting
2. Disparities
3. Education
4. Novel Procedures
5. Practice Management

The Task Force completed the first part of its task and submitted its draft report to the EC, which can be found [here](#).

From the nearly 40 total recommendations, the Task Force selected its top 10 recommendations. These ten recommendations were submitted to the MSTS membership in the form of a survey, asking respondents to score each recommendation and offer feedback. Thanks to the more than 50 MSTS members who completed the survey. The results of the survey can be seen [here](#).

The Task Force is now starting the second and final part of its task. It held its most recent meeting on January 10, 2024. Work will be done in four committees:

1. Fellowships
2. Guidelines and Evidence Based Medicine

3. Industry Relations
4. Research

We anticipate finishing completing our report by July 2024. At that point the Task Force will be dissolved. During this interval, a standing Skeletal Metastases Committee will be formed to execute the recommendations of the Task Force. If you have any ideas or suggestions, please do not hesitate to [contact me](#) or any Task Force member.



Global Modular Replacement System

One system, one vision, one solution

- Incorporates decades of experience with the Kinematic Rotating Hinge (KRH), Modular Replacement System (MRS) and Modular Rotating Hinge (MRH)
- Designed to help retain the quality of life for patients who require radical bone resection for proximal femur, distal femur, total femur and proximal tibia
- Offers various options of lengths, materials and fixation in stemmed configurations to help surgeons meet patients' needs

A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery.

The information presented is intended to demonstrate the breadth of Stryker's product offerings. A surgeon must always refer to the package insert, product label and/or instructions for use before using any of Stryker's products. The products depicted are CE marked according to the Medical Device Directive 93/42/EEC. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your sales representative if you have questions about the availability of Stryker's products in your area.

Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: GMRS, Stryker. All other trademarks are trademarks of their respective owners or holders.

Guidelines and Evidence Based Medicine Committee Update –

Nicholas Tedesco, DO, Chair

The Guidelines and Evidence-Based Medicine (GEBM) Committee is proud to close out 2023 and look forward to another productive year in 2024. We continue to work hard to serve the MSTs membership and orthopedic oncologists worldwide. We are currently busy negotiating a combined, multidisciplinary, clinical practice guideline (CPG) with the North American Spine Society (NASS) on management of multiple myeloma and metastatic disease in the mobile spine. We are hoping to get started on this in the first quarter of 2024. Additionally, efforts have been forwarded to increase diversity, collaboration, and global outreach by partnering with both EMSOS (European Musculo-Skeletal Oncology Society) and SLATME (Sociedad Latinoamericana de Tumores Musculo Esqueleticos) on all future CPG's. Each of these groups are excited to combine with the MSTs GEBM and bring

their unique and valuable skills, knowledge, and experience outside of North America to the table.

Other future plans in 2024 will be to submit our first ever, MSTs-sponsored, CPG on management of metastatic disease of the humerus to JAAOS for publication. Please be on the lookout for it in the coming months! We will also continue to produce yearly novel clinical practice assessments: objective, evidence-based, literature reviews of new and emerging technologies. The first series have been published on the GEBM link of the MSTs website, with the plan for future series to be released each year before the annual meeting. Please check them out! The current topics posted include:

1. 3-D patient specific instrumentation in bone sarcoma
2. The ENLIVEN clinical trial

3. Radiofrequency ablation for skeletal metastases
4. Use of doxycycline in aneurysmal bone cysts
5. Use of radiolucent implants in surgery for musculoskeletal oncology

The GEBM Committee is here to serve the entire MSTs membership! If you have any ideas for clinical practice guidelines, appropriate use criteria, novel clinical practice assessments, systematic reviews, or quality improvement projects, please do not hesitate to reach out to myself or any GEBM committee members. Other current members include: Yee-Cheen Doung, Pietro Ruggieri, Matthew Colman, Hennock Wolde-Semait, and our 2 new recent additions: Alexander Lazarides and Dipak Ramkumar. Welcome aboard, Dr.'s Lazarides and Ramkumar!

Applications Are Now Open for the MSTs Hatcher Fellowship – Deadline to Apply is March 1, 2024

The Hatcher Pathology Fellowship was established in 1983, named in honor of the late C. Howard Hatcher, MD. The Fellowship was developed by Dr. Hatcher's former residents and friends in the spirit of enriching orthopaedic surgeons with post-graduate experience in musculoskeletal oncology, with an anticipation of an academic career in musculoskeletal oncology. The fellowship is offered annually to US and international orthopaedic surgeons who have completed an accredited orthopaedic surgery residency or its equivalent.

Applications are now being accepted for the MSTs Hatcher Fellowship. Applicants must be US or international orthopaedic surgeons with planned or completed post-graduate experience in musculoskeletal oncology, with an anticipation of an academic career in musculoskeletal oncology and must have completed an orthopaedic surgery residency or its equivalent.

Interested applicants should submit a completed application describing the potential fellowship opportunity in detail,

and explaining why the applicant believes the opportunity provides enrichment in the spirit of the Hatcher Fellowship. The Hatcher Fellowship is a one-time only award of up to \$8,500.

For additional eligibility requirements and to apply, [please click here](#). Application deadline is **March 1, 2024**.





OsteoCool™ radiofrequency ablation system

One treatment. Sustained cancer pain relief.

The OPuS One study, now published in CardioVascular and Interventional Radiology, reveals remarkable findings in a large, multi-center clinical study.

It showcases rapid pain relief within as few as 3 days, sustained relief at 1 year post-procedure, and no delayed skeletal events, independent of radiation.¹



Learn more about the OsteoCool™ radiofrequency ablation system and our clinical evidence at [medtronic.com/osteocool](https://www.medtronic.com/osteocool).

Risks include tissue damage; pulmonary embolism; spinal cord or nerve roots puncture potentially causing paresis and paralysis.

1. Levy J, David E, Hopkins T, Morris J, Tran ND, Farid H, Massari F, O'Connell WG, Vogel A, Gangi A, Sunenshine P, Dixon R, Von der Höh N, Bagla S. Radiofrequency Ablation Provides Rapid and Durable Pain Relief for the Palliative Treatment of Lytic Bone Metastases Independent of Radiation Therapy: Final Results from the OsteoCool Tumor Ablation Post-Market Study. Cardiovasc Intervent Radiol. 2023 May;46(5):600-609.

©2023 Medtronic. All rights reserved. UC202405064aEN

Welcome New MSTS Members!

During the October Executive Committee meeting, we were pleased to approve 10 new members into MSTS and 9 members who changed their membership to the next member category. Welcome to our new members and congratulations to those members who are advancing in their careers.

Active Members

Annie Arteau, MD, FRCSC
William Eward, MD, DVM
Yvette Ho, MD – new member
Eugene S. Jang, MD, MS
Adam Lindsay, MD
Geoffrey W. Siegel, MD
Brian Walczak, DO, PhD
Matthew T. Wallace, MD, MBA
Zeke Walton, MD

Candidate Members

Rashmi Agarwal, MD – new member
Paul Gagnet, MD
Matthew C. Hess, MD – new member
James P. Norris, IV, MD – new member
Meagan Tibbo, MD – new member
Spencer Woolwine, MD – new member

Resident Members

Nicole Levine, MD – new member
Christopher Moran, MD – new member
Brianna Siracuse, MD – new member
Nathan P. Thomas, Jr., MD, PhD
– new member

If you have a colleague who would like to become a member of MSTS, or if your member category is ready to be updated, the next membership application deadline will be Monday, **August 5, 2024**.


[Click here](#) to apply as a new member or to update your membership!

Thank You Donors

Thank you to the following MSTS Donors

*Donations Deposited to MSTS
September 1, 2022 through
December 31, 2023*

John H. Alexander, MD
Edward Athanasian, MD
Tessa Balach, MD
Nicholas Bernthal, MD
Odion Binitie, MD
Gary Bos, MD
Scot Brown, MD
Emily Carmody, MD
Felix Cheung, MD
Kenneth Chirba, MD
Matthew Colman, MD
Gary E. Friedlaender, MD
Mark C. Gebhardt, MD
Michelle Ghert, MD, FRCSC
Steven Gitelis, MD
Kenneth Gundle, MD
Derek Hansen, MD
John H. Healey, MD, FACS
Eric R. Henderson, MD
David Hennessey, MD
David M. King, MD
Brandon Jonard, MD
Joshua Lawrenz, MD
Bennie Lindeque, MD
Joel Mayerson, MD
Susan McDowell, MD
Benjamin J. Miller, MD, MS
Carol Morris, MD, MS
Michael Mott, MD
John Neilson, MD
Vincent Ng, MD
Lukas M. Nystrom, MD
Mary O'Connor, MD
Richard O'Donnell, MD
Rajiv Rajani, MD
Richard Terek, MD
William G. Ward, MD, FACS
Kristy Weber, MD
Adam Wooldridge, MD
Rosanna Wustrack, MD
Melissa Zimel, MD



Become a MSTS Member

Membership Application Deadline: **August 5, 2024**

Details [here](#).

Delivering **Comprehensive Solutions** for **Significant Bone Loss**

DISCOVER OUR
LIMB SALVAGE
SOLUTIONS



ZIMMER BIOMET

This material is intended for health care professionals. All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet. Distribution to any other recipient is prohibited. For product information, including indications, contraindications, warnings, precautions, potential adverse effects and patient counseling information, see the package insert and www.zimmerbiomet.com. Check for country product clearances and reference product specific instructions for use. ©2023 Zimmer Biomet • A0087.1-GLBL-en-Issue Date-2023-08

MSTS 2023 ANNUAL MEETING ACKNOWLEDGMENTS

THANK YOU

The Musculoskeletal Tumor Society extends sincere appreciation to the following exhibitors for their generous support of the MSTS 2023 Annual Meeting.



DIAMOND SPONSORS



Medtronic



stryker

SPONSORS

3D Side
Acera Surgical
AAOS/MsTR Registry
Biocomposites
Carbofix Orthopedics, Inc.
Deciphera Pharmaceuticals
IlluminOss Medical, Inc.
Implantcast North America

Inhibrx
Insight Surgery
Integrum, Inc.
Link
Merete Technologies, Inc.
MTF Biologics
OsteoCentric Technologies
Signature Orthopaedics – USA
Vector Surgical